I am fairly new to the forum and I am going to make my first real post.

Here are my thoughts on one comparison that can be made to make a possible valuation for MNKD.

Amylin (AMLN) developed the drug called Bydureon, an injected (just once a week) slow release GLP-1 drug. This drug, in the presence of high blood glucose, signals the pancreas to release insulin. I am not a doctor, so my understanding of the drug is not perfect, but I believe that this drug addresses the control of diabetes for a subset of the population that could use afrezza. I have read good things about this drug in controlling A1C's. It can only be used by type 2 patients, and I don't think it is appropriate for all of them.

I believe that it could be a strong competitor to Mannkind’s MKC253: GLP-1/Technosphere. http://www.mannkindcorp.com/product-pipeline-mkc253.htm. It may also compete with afrezza because it is fast acting.

My point about valuation is that Amylin was recently acquired by Bristol-Meyers Squibb.

http://finance.yahoo.com/news/bristol-myers-squibb-completes-acquisition-113000269.html;_ylt=A2KLOzIhmTFQFDYAvCyTmYlQ

There were 164.28 million shares outstanding, and shares were acquired at $31. This is a valuation of over $5 billion. So, maybe $5 billion is a floor on the valuation that Mannkind might have after approval and production commences.

Assuming the worst case dilution of 300 million shares, or a total of 500 million, would equate to a price of $10 per share.

Any thoughts?

Bob